OS Therapies (OSTX) Total Current Liabilities (2023 - 2026)
OS Therapies' (OSTX) quarterly Total Current Liabilities came in at $17.0 million in Q1 2026, up 379.4% YoY from $3.5 million in Q1 2025, and up 44.1% on a QoQ basis from $11.8 million in Q4 2025.
OS Therapies (OSTX) Total Current Liabilities (2023 - 2026) Analysis & Trends
OS Therapies (OSTX) has 4 years of Total Current Liabilities data on file, last reported at $17.0 million in Q1 2026.
- Quarterly Total Current Liabilities rose 379.4% year-over-year to $17.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.0 million (up 379.4% YoY) and the FY2025 annual result came in at $11.8 million, up 154.24% from the prior year.
- Total Current Liabilities rose to $17.0 million in Q1 2026, from $11.8 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $28.3 million in Q2 2024 to a low of $2.6 million in Q3 2024.
- A 4-year average of $12.7 million and a median of $8.2 million in 2024 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2025 — Total Current Liabilities tumbled 87.78% — and 2026, when it surged 379.4%.
- Tracing OSTX's Total Current Liabilities over 4 years: stood at $24.7 million in 2023, then slumped by 81.28% to $4.6 million in 2024, then surged by 154.24% to $11.8 million in 2025, then soared by 44.1% to $17.0 million in 2026.
- The last three Total Current Liabilities figures came in at $17.0 million (Q1 2026), $11.8 million (Q4 2025), and $4.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | OS Therapies | 19.31 Mn | 19.31 Mn | - | 20.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.95 Mn |
| Dec 31, 2025 | 11.76 Mn |
| Sep 30, 2025 | 4.15 Mn |
| Jun 30, 2025 | 3.46 Mn |
| Mar 31, 2025 | 3.54 Mn |
| Dec 31, 2024 | 4.63 Mn |
| Sep 30, 2024 | 2.58 Mn |
| Jun 30, 2024 | 28.31 Mn |
| Mar 31, 2024 | 26.46 Mn |
| Dec 31, 2023 | 24.71 Mn |